C. Eric Schwartz

Vice President of Drug Discovery at Cedilla Therapeutics, Inc.

C. Eric Schwartz

C. Eric Schwartz

Vice President of Drug Discovery at Cedilla Therapeutics, Inc.

Overview
RelSci Relationships

1007

Relationships
RelSci Relationships are individuals C. Eric Schwartz likely has professional access to. A relationship does not necessarily indicate a personal connection.

President, Chief Executive Officer & Director at C4 Therapeutics, Inc.

Relationship likelihood: Average

Entrepreneur at Polaris Partners

Relationship likelihood: Average

Chief Scientific Officer at Avila Therapeutics, Inc.

Relationship likelihood: Average

President, Chief Executive Officer & Director at Cedilla Therapeutics, Inc.

Relationship likelihood: Average

Chief Scientific Officer at Cedilla Therapeutics, Inc.

Relationship likelihood: Average

Chief Human Resources Officer at Cedilla Therapeutics, Inc.

Relationship likelihood: Average

Founder at Cedilla Therapeutics, Inc.

Relationship likelihood: Average

Founder at Cedilla Therapeutics, Inc.

Relationship likelihood: Average

Vice President of Proteomics & Chemical Biology at Cedilla Therapeutics, Inc.

Relationship likelihood: Average

Vice President of Biology at Cedilla Therapeutics, Inc.

Relationship likelihood: Average

Paths to C. Eric Schwartz
Potential Connections via
Relationship Science
You
C. Eric Schwartz
Vice President of Drug Discovery at Cedilla Therapeutics, Inc.
Education

The University of Wisconsin–Madison has long been recognized as one of America's great universities. A public, land-grant institution, UW–Madison offers a complete spectrum of liberal arts studies, professional programs and student activities. Spanning 936 acres along the southern shore of Lake Mendota, the campus is located in the city of Madison.

Career History
Vice President of Drug Discovery
2018 - Current

Cedilla Therapeutics, Inc. operats as a biotechnology company. It engages in discovering and exploiting insights into protein stability. The company was founded by Alan D. D’Andrea, Steve Gygi, Matthew P. Jacobson, William G. Kaelin, Jr. and Jack Taunton on September 6, 2017 and is headquartered in Cambridge, MA.

Vice President-Chemistry
2006 - Prior

Resolvyx Pharmaceuticals, Inc. discovers and develops therapeutics for inflammatory diseases. Its products include RX-10001, RX-10045 and RX-20001. The firm's focus is to develop a new class of medicines called Resolvins for the treatment of a range of ophthalmic diseases. The company was founded by Daniel Goodman, Charles N. Serhan, Per Gjorstrup and Thomas E. Van Dyke in June 20, 2001 and is headquartered in Cambridge, MA.

Senior Director-Chemistry
Prior

Avila Therapeutics, Inc. researches and develops covalent drugs. The company was founded in 2007 and is headquartered in Summit, NJ.

Transactions
Details Hidden

Resolvyx Pharmaceuticals, Inc. raised money in a private placement transaction

Details Hidden

Resolvyx Pharmaceuticals, Inc. raised money in a private placement transaction

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by C. Eric Schwartz. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of C. Eric Schwartz's profile does not indicate a business or promotional relationship of any kind between RelSci and C. Eric Schwartz.